# Kaika Biotechnology

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/kaika-biotechnology

- Industry: Biotechnology
- Headquarters: Shanghai, China
- Website: www.kactusbio.com.cn
- Total disclosed funding: $34M
- Latest round: Series B (Oct 20, 2022)
- Investors on record: 9

## About

Based in Shanghai, China and founded in 2018, Kaika Biotechnology operates as a target protein developer that provides target protein R&D platform.The company has completed A+ round of financing of over RMB 100 million, which was led by Bencao Investment and Sherpahp Investment, followed by Taifu Capital, SDIC Venture Capital and Divine Investment. In January 2022, the company passed ISO 13485:2016 certification. In May 2022, neoX has become the strategic partner of Kaika Biotechnology.

The company provides its own research and development platform SAMSTM (Structure Aided design and Multiplex Screening), it focuses on delivering protein and antibody products and technologies for immune therapy and IVD customers. Its products include mRNA vaccine GMP raw material enzyme, gene editing enzyme, universal nuclease and VLP superantigen protein. The company's solutions include exclusive SPR customized detection service for MHC polypeptide complex expression, customized low endotoxin protein and customized detection service for VLP protein exclusive SPR.

## Funding rounds

- Series B, Oct 20, 2022, $28M — New Alliance Capital, Shanghai Growth Investment, Lingang Lanwan Fund
- Series A, Jul 8, 2021 — Divine Capital, 3E Bioventures Capital, TF Capital, SDIC Venture Capital, Sherpa Healthcare Partners
- Series A, Sep 28, 2020, $5.9M — Biocytogen Biotechnology, SDIC Venture Capital

## Investors

- Biocytogen Biotechnology — Series A
- SDIC Venture Capital (https://capitalatlas.ai/funds/sdic-venture-capital) — Series A
- Divine Capital (https://capitalatlas.ai/funds/divine-capital) — Series A
- 3E Bioventures Capital (https://capitalatlas.ai/funds/3e-bioventures-capital) — Series A
- TF Capital — Series A
- Sherpa Healthcare Partners (https://capitalatlas.ai/funds/sherpa-healthcare-partners) — Series A
- New Alliance Capital (https://capitalatlas.ai/funds/new-alliance-capital) — Series B
- Shanghai Growth Investment (https://capitalatlas.ai/funds/shanghai-growth-investment) — Series B
- Lingang Lanwan Fund — Series B